{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-002542","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2023-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.292063+00:00","generated_at":"2026-06-16T22:29:10.843411+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio raises ~$2M in registered direct offering with warrants, amends existing warrants","bullets":["Issued 353,983 shares at $5.65/share, gross proceeds ~$2.0M; net ~$1.65M after fees.","Concurrent private placement: Series A (5.5-yr) and Series B (18-mo) warrants for up to 707,966 shares at $5.40.","Amended 191,619 existing warrants from exercise prices $26.52–$2,079.00 down to $5.40 for $0.125 each.","Net proceeds for immuno-oncology development, working capital, and general corporate purposes.","Offering closed April 20, 2023; H.C. Wainwright acted as exclusive placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-002542","json":"https://secwatch.observer/filing/0001683168-23-002542.json","markdown":"https://secwatch.observer/filing/0001683168-23-002542.md","text":"https://secwatch.observer/filing/0001683168-23-002542.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823002542/0001683168-23-002542-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823002542/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T22:29:10.843411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6a98796afb004f2ec0ddfdfc704c98d3b56321c5","claim":"Phio Pharmaceuticals Corp. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-01-20).","evidence_excerpt":"Pursuant to an engagement letter, dated as of January 20, 2023 (the “Engagement Letter”), between the Company and H.C. Wainwright & Co., LLC, or the placement agent","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823002542/0001683168-23-002542-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Effective","value":"2023-01-20"}],"fact_type":"material_agreement"},{"claim_id":"93b78c194f5151dc9ae7e8fbd50b3e165887d8ae","claim":"Phio Pharmaceuticals Corp. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $1.65 million (effective 2023-04-18).","evidence_excerpt":"On April 18, 2023, Phio Pharmaceuticals Corp. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”) relating to the registered direct offering and sale of 353,983 shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823002542/0001683168-23-002542-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $1.65 million"},{"label":"Effective","value":"2023-04-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}